In This Article:
The United States market has shown robust performance recently, rising 1.1% over the last week and an impressive 32% over the past year, with earnings projected to grow by 15% annually. In such a dynamic environment, identifying small-cap stocks that are perceived as undervalued and exhibit insider buying can offer intriguing opportunities for investors seeking potential value plays.
Top 10 Undervalued Small Caps With Insider Buying In The United States
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Hanover Bancorp | 9.5x | 2.2x | 47.36% | ★★★★★☆ |
Columbus McKinnon | 21.8x | 1.0x | 40.67% | ★★★★★☆ |
Franklin Financial Services | 9.8x | 1.9x | 37.53% | ★★★★☆☆ |
HighPeak Energy | 11.8x | 1.5x | 36.60% | ★★★★☆☆ |
Delek US Holdings | NA | 0.1x | -675.65% | ★★★★☆☆ |
German American Bancorp | 14.5x | 4.8x | 45.32% | ★★★☆☆☆ |
Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
Orion Group Holdings | NA | 0.3x | -100.21% | ★★★☆☆☆ |
Sabre | NA | 0.4x | -35.11% | ★★★☆☆☆ |
Industrial Logistics Properties Trust | NA | 0.7x | -222.36% | ★★★☆☆☆ |
Let's take a closer look at a couple of our picks from the screened companies.
Phibro Animal Health
Simply Wall St Value Rating: ★★★★★☆
Overview: Phibro Animal Health is a company that specializes in animal health products, mineral nutrition, and performance products with a market capitalization of approximately $0.54 billion.
Operations: Phibro Animal Health generates revenue primarily from three segments: Animal Health, Mineral Nutrition, and Performance Products. The company's gross profit margin has shown a varied trend over the periods, reaching 30.82% in June 2024. Operating expenses have increased over time, impacting net income margins, which declined to 0.24% by June 2024.
PE: 404.9x
Phibro Animal Health, a smaller player in the U.S. market, is catching attention for its potential value. Recent insider confidence is evident as they purchased shares between July and August 2024. Despite challenges like a drop in net income to US$2.42 million for the year ending June 2024, Phibro projects sales growth of up to US$1.09 billion in fiscal 2025 driven by their Animal Health segment's expansion and recovery elsewhere.
Couchbase
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Couchbase is a software company specializing in NoSQL cloud database solutions with a market cap of $0.84 billion.
Operations: The company generates revenue primarily from its Software & Programming segment, with recent figures reaching $198.82 million. Its cost structure includes significant operating expenses, notably in sales and marketing as well as research and development. The gross profit margin has shown fluctuations, recently recorded at 88.74%.